Core Viewpoint - 恒瑞医药 and its subsidiaries have received approval from the National Medical Products Administration for multiple clinical trials of new drug candidates, indicating a strong pipeline and ongoing investment in innovative therapies [1] Group 1: Clinical Trial Approvals - The company has received approval for clinical trials for several drugs, including SHR-9839, SHR-A2009, SHR-1826, HRS-4642, and others [1] - SHR-9839 is a humanized antibody drug aimed at treating advanced solid tumors, with a cumulative R&D investment of approximately 72.31 million yuan [1] - SHR-A2009 is a HER3-targeted antibody-drug conjugate, with no similar drugs approved globally, and a cumulative R&D investment of about 227 million yuan [1] Group 2: Market Potential and R&D Investments - SHR-1826 is a c-MET-targeted antibody-drug conjugate, with a cumulative R&D investment of around 101 million yuan [1] - HRS-4642 is a KRASG12D inhibitor, with a cumulative R&D investment of approximately 191 million yuan [1] - The approved drug, 阿得贝利单抗, is indicated for first-line treatment of extensive-stage small cell lung cancer, with a projected global sales of similar products totaling about 9.648 billion USD in 2024 and a cumulative R&D investment of approximately 969 million yuan [1] Group 3: Future Drug Approvals and Sales Projections - 注射用瑞康曲妥珠单抗 is expected to be approved in China by May 2025 for HER2-mutant non-small cell lung cancer, with projected global sales of similar products totaling around 6.557 billion USD in 2024 and a cumulative R&D investment of about 1.415 billion yuan [1] - SHR-A2102 is a Nectin-4-targeted antibody-drug conjugate, with projected global sales of about 1.949 billion USD in 2024 and a cumulative R&D investment of approximately 248 million yuan [1] - HRS-7058 is a KRASG12C inhibitor, with projected global sales of similar products totaling around 485 million USD in 2024 and a cumulative R&D investment of about 69.57 million yuan [1]